Abstract
Background: Long non-coding RNAs (lncRNA) have influenced numerous biology processes, which has provoked great interest. Not only that, LncRNA DUXAP8 mediates tumorigenesis by affecting the activity of miRNAs, signaling pathways, and oncogene.
Methods: The functions of DUXAP8 have been summarized by reading relevant articles on PubMed.
Results: lncRNA DUXAP8 acts as an oncogene in most tumors. The abnormal overexpression is associated with the proliferation, invasion, migration, and anti-autophagy of tumors. DUXAP8 exerts promotion on Akt / mTOR signaling pathway, facilitating the occurrence of tumors. Furthermore, DUXAP8 affects the activity of miRNAs and proteins, showing its significant potential as a therapeutic target in human cancers.
Conclusion: LncRNA DUXAP8 has been identified as an indispensable therapeutic target of the tumors, providing clinical treatment plans.
Keywords: Long non-coding RNA, DUXAP8, tumorigenesis, biomarker, potential therapeutic target, carcinoma.
[http://dx.doi.org/10.1038/onc.2017.184] [PMID: 28604750]
[http://dx.doi.org/10.3389/fgene.2020.00666] [PMID: 32849765]
[http://dx.doi.org/10.1007/s13577-020-00398-8] [PMID: 32749665]
[http://dx.doi.org/10.2147/OTT.S243542] [PMID: 32801745]
[http://dx.doi.org/10.1016/j.brainres.2020.146947] [PMID: 32522628]
[http://dx.doi.org/10.18632/oncotarget.11075] [PMID: 28881724]
[PMID: 29771416]
[http://dx.doi.org/10.18632/aging.102152] [PMID: 31409759]
[http://dx.doi.org/10.7150/jca.47902] [PMID: 32922554]
[http://dx.doi.org/10.2147/OTT.S214336] [PMID: 31571902]
[http://dx.doi.org/10.1002/cam4.2861] [PMID: 32022476]
[http://dx.doi.org/10.1016/j.omto.2020.10.010] [PMID: 33313387]
[http://dx.doi.org/10.18632/aging.102226] [PMID: 31541993]
[PMID: 32271433]
[http://dx.doi.org/10.1042/BSR20200884] [PMID: 33269379]
[http://dx.doi.org/10.3390/ijms20225758] [PMID: 31744051]
[http://dx.doi.org/10.2147/OTT.S235643] [PMID: 33149618]
[PMID: 31364111]
[http://dx.doi.org/10.2147/OTT.S167853] [PMID: 30323619]
[PMID: 29917188]
[http://dx.doi.org/10.1016/j.jpedsurg.2019.08.032] [PMID: 31522796]
[http://dx.doi.org/10.18632/oncotarget.21206] [PMID: 29152119]
[http://dx.doi.org/10.1016/j.celrep.2018.03.075] [PMID: 29617669]
[http://dx.doi.org/10.12659/MSM.910054] [PMID: 30317248]
[http://dx.doi.org/10.1186/s13046-019-1473-8] [PMID: 31775815]
[http://dx.doi.org/10.1002/cam4.1536] [PMID: 29926523]
[http://dx.doi.org/10.1080/14737159.2019.1660645] [PMID: 31448971]
[http://dx.doi.org/10.1038/s41388-018-0382-1] [PMID: 29970904]
[http://dx.doi.org/10.3892/ol.2019.9994] [PMID: 30867791]
[http://dx.doi.org/10.1097/CAD.0000000000000936] [PMID: 32304409]